Home › Glioblastoma
Glioblastoma clinical trials recruiting in the U.S.
157 studies for Glioblastoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY30 studies
- Houston, TX27 studies
- Boston, MA27 studies
- Los Angeles, CA23 studies
- Durham, NC19 studies
- San Francisco, CA19 studies
- Chicago, IL15 studies
- Rochester, MN14 studies
- Washington, DC14 studies
- Columbus, OH14 studies
- Miami, FL14 studies
- Jacksonville, FL13 studies
- Cleveland, OH12 studies
- St. Louis, MO12 studies
- Aurora, CO12 studies
- Philadelphia, PA11 studies
- Baldwin Park, CA11 studies
- Baltimore, MD10 studies
- Salt Lake City, UT10 studies
- Atlanta, GA9 studies
- Nashville, TN9 studies
- Winston-Salem, NC9 studies
- Birmingham, AL9 studies
- Pittsburgh, PA8 studies
- Seattle, WA8 studies
- Madison, WI7 studies
- Edison, NJ7 studies
- Dallas, TX7 studies
- Phoenix, AZ7 studies
- Ann Arbor, MI7 studies
- San Antonio, TX7 studies
- San Diego, CA7 studies
- Orange, CA6 studies
- Cincinnati, OH6 studies
- Tampa, FL6 studies
- Mountain View, CA6 studies
- Irvine, CA5 studies
- Milwaukee, WI5 studies
- Queens, NY5 studies
- Scottsdale, AZ5 studies
By state
- Alabama9 studies
- Arizona13 studies
- California43 studies
- Colorado15 studies
- Connecticut5 studies
- District of Columbia9 studies
- Florida30 studies
- Georgia10 studies
- Illinois16 studies
- Indiana3 studies
- Iowa4 studies
- Kansas3 studies
- Kentucky6 studies
- Maine3 studies
- Maryland14 studies
- Massachusetts28 studies
- Michigan11 studies
- Minnesota19 studies
- Missouri13 studies
- Nebraska4 studies
- New Jersey9 studies
- New York33 studies
- North Carolina26 studies
- Ohio23 studies
- Oklahoma4 studies
- Pennsylvania19 studies
- Rhode Island3 studies
- South Carolina4 studies
- Tennessee10 studies
- Texas33 studies
- Utah10 studies
- Virginia11 studies
- Washington9 studies
- Wisconsin10 studies
Recently updated studies
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Recruiting
Ages 18 to 85 · All sexes · Updated Nov 12, 2026 · NCT06910306A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06914128Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07927595A Phase I Clinical Study of YN003 in the Treatment of Glioma
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Nov 10, 2026 · NCT07929909Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07195591Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07664579Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT05432804PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 6, 2026 · NCT06161519Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Nov 5, 2026 · NCT00083512Anti-GD2 ADC M3554 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06641908Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05139056A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07464925Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Recruiting
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07628647A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT03970447Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Nov 2, 2026 · NCT05106296GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07301268Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07775534A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05303467A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
RecruitingPhase 1
Ages 4 and older · All sexes · Updated Oct 30, 2026 · NCT04573140A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05765812Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07708961Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07544992Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Oct 23, 2026 · NCT07346144Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06815029From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.